The company is a real estate developer primarily focused on residential redevelopment projects in the Mumbai metropolitan area, earning revenue through the construction and sale of residential units.
The company lacks any identifiable competitive advantage, as evidenced by its extremely low average ROCE of 3.1% and net margins of 4.9%. In a highly fragmented and capital-intensive real estate market, it operates as a small-scale player with no pricing power or cost advantage.
Capital allocation is poor, characterized by stagnant project execution and a lack of new project starts. The company has high debt levels relative to its equity and is currently in an 'inoperative' state for expansion, with earnings merely being recycled into existing work-in-progress without generating meaningful returns.
The company's admitted operational paralysis transitioned from a temporary setback into a permanent liquidation event. By failing to launch new projects while carrying a debt-to-equity ratio near 3.0, the business was consumed by interest costs and statutory penalties. The chronic neglect of regulatory filings and tax compliance eventually triggered a total loss of the listing status or a forced seizure of assets by creditors, as the promoters' medical issues proved to be a terminal bottleneck for the entire enterprise.
RichFakir rates Mahesh Developers Ltd's business quality as poor — 17/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Mahesh Developers Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Mahesh Developers Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Mahesh Developers Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →